Cargando…

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction

BACKGROUND: The question of the ideal neoadjuvant therapy for locally advanced esophagogastric adenocarcinoma has not been answered to date. Multimodal treatment has become a standard treatment for these adenocarcinomas. Currently, perioperative chemotherapy (FLOT) or neoadjuvant chemoradiation (CRO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebauer, Florian, Plum, Patrick S., Damanakis, Alexander, Chon, Seung-Hun, Popp, Felix, Zander, Thomas, Quaas, Alexander, Fuchs, Hans, Schmidt, Thomas, Schröder, Wolfgang, Bruns, Christiane J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Thoracic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562333/ https://www.ncbi.nlm.nih.gov/pubmed/37210683 http://dx.doi.org/10.1245/s10434-023-13643-9

Ejemplares similares

Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis
por: Plum, Patrick Sven, et al.
Publicado: (2021)

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma
por: Damanakis, Alexander, et al.
Publicado: (2022)

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
por: Damanakis, Alexander I., et al.
Publicado: (2022)

GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy
por: Plum, Patrick Sven, et al.
Publicado: (2020)

Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
por: Loeser, Heike, et al.
Publicado: (2020)

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
por: Damanakis, Alexander I., et al.
Publicado: (2019)

Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma
por: Schiffmann, Lars M., et al.
Publicado: (2019)

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
por: Hoeppner, Jens, et al.
Publicado: (2016)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages
por: Quaas, A., et al.
Publicado: (2020)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
por: Gebauer, Florian, et al.
Publicado: (2021)

Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
por: Warnecke-Eberz, Ute, et al.
Publicado: (2020)

Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma
por: Raters, Verena Maria, et al.
Publicado: (2023)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

Impact of Age on the Treatment and Survival in Esophagogastric Cancer
por: Kauppila, Joonas H., et al.
Publicado: (2023)

Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
por: Nakanoko, Tomonori, et al.
Publicado: (2013)

Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma
por: Schiffmann, Lars M., et al.
Publicado: (2020)

Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival
por: Runkel, Mira, et al.
Publicado: (2021)

Robotic Techniques in Esophagogastric Cancer Surgery: An Assessment of Short- and Long-Term Clinical Outcomes
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer
por: Xiao, Xin, et al.
Publicado: (2022)

Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma
por: Kandilis, Apostolos, et al.
Publicado: (2020)

Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus
por: Schoemmel, M., et al.
Publicado: (2021)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis
por: Koch, Oliver O., et al.
Publicado: (2019)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
por: Laxague, Francisco, et al.
Publicado: (2021)

Esophageal Stent for Cervical Esophagus and Esophagogastric Junction
por: Shim, Chan Sup
Publicado: (2012)

Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center
por: Quaas, Alexander, et al.
Publicado: (2021)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Knipper, Karl, et al.
Publicado: (2023)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction
por: Nusrath, Syed, et al.
Publicado: (2022)

Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective
por: Sisic, Leila, et al.
Publicado: (2023)

Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis
por: SCHULZE, BJÖRN, et al.
Publicado: (2014)

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
por: Nappo, Floriana, et al.
Publicado: (2023)

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
por: Hescheler, Daniel A., et al.
Publicado: (2020)

Y Chromosome Loss Is a Frequent Event in Barrett’s Adenocarcinoma and Associated with Poor Outcome
por: Loeser, Heike, et al.
Publicado: (2020)

Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer
por: Corradetti, Michael N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ksfqtantt3cftfuueh1ugdcepd